Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has scheduled its second quarter 2025 earnings release and conference call for August 5, 2025. The financial results will be released after market close, followed by a conference call at 4:30 PM ET.

Management will discuss the company's Q2 2025 financial performance and provide a business update during the call. Investors can access the live webcast through Myriad's Investor Relations website, while those preferring telephone participation must register to receive dial-in details.

News Market Reaction – MYGN

-1.22%

-1.22% Session move

In the trading session that priced this news, MYGN declined 1.22%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(224) 875-4493
PR@myriad.com

FAQ

When will Myriad Genetics (MYGN) report Q2 2025 earnings?

Myriad Genetics will release Q2 2025 earnings on Tuesday, August 5, 2025 after market close, with a conference call at 4:30 PM ET.

How can investors access Myriad Genetics' Q2 2025 earnings call?

Investors can access the call through a live webcast at investor.myriad.com or via telephone by registering to receive a dial-in number and PIN.

What time is Myriad Genetics' Q2 2025 earnings call?

The earnings conference call is scheduled for 4:30 PM ET on Tuesday, August 5, 2025.

Where can I find the replay of Myriad Genetics' Q2 2025 earnings call?

An archived webcast of the call will be available at investor.myriad.com following the conference call.